.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Fish and Richardson
Johnson and Johnson
Mallinckrodt
Dow
Merck
Fuji
Citi
McKesson
Boehringer Ingelheim

Generated: November 21, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021986

« Back to Dashboard
NDA 021986 describes SPRYCEL, which is a drug marketed by Bristol Myers Squibb and is included in one NDA. It is available from two suppliers. There are five patents protecting this drug and three Paragraph IV challenges. Additional details are available on the SPRYCEL profile page.

The generic ingredient in SPRYCEL is dasatinib. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the dasatinib profile page.

Summary for 021986

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:5
Therapeutic Class:Antineoplastics
Formulation / Manufacturing:see details

Pharmacology for NDA: 021986

Medical Subject Heading (MeSH) Categories for 021986

Suppliers and Packaging for NDA: 021986

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SPRYCEL
dasatinib
TABLET;ORAL 021986 NDA E.R. Squibb & Sons, L.L.C. 0003-0524 0003-0524-11 1 BOTTLE in 1 CARTON (0003-0524-11) > 60 TABLET in 1 BOTTLE
SPRYCEL
dasatinib
TABLET;ORAL 021986 NDA E.R. Squibb & Sons, L.L.C. 0003-0527 0003-0527-11 1 BOTTLE in 1 CARTON (0003-0527-11) > 60 TABLET in 1 BOTTLE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength20MG
Approval Date:Jun 28, 2006TE:ABRLD:Yes
Patent:► SubscribePatent Expiration:Jun 28, 2020Product Flag?YSubstance Flag?YDelist Request?
Patented Use:A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER
Patent:► SubscribePatent Expiration:Jun 28, 2020Product Flag?YSubstance Flag?YDelist Request?
Patented Use:A METHOD FOR THE TREATMENT OF CANCER
Patent:► SubscribePatent Expiration:Apr 13, 2020Product Flag?Substance Flag?Delist Request?
Patented Use:A METHOD FOR THE TREATMENT OF CANCER


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Novartis
US Department of Justice
Farmers Insurance
Queensland Health
US Army
UBS
Healthtrust
Boehringer Ingelheim
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot